MedTrace Logo

A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis

NCT00938587 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2023-11-22

Study results available
· View outcomes & findings →

Summary

This study will investigate the safety and efficacy of an investigational drug, PF-04171327 on the signs and symptoms of rheumatoid arthritis in patients that require glucocorticoids while on background methotrexate. This study will also look at the response of chemical and biological markers in rheumatoid arthritis patients. Lastly, this study will measure the PK (amount of drug in the blood) of methotrexate while patients may be taking PF-04171327.

Conditions

Interventions

DRUG

PF-04171327 10 mg

PF-04171327 10 mg tablet every day for 14 days

OTHER

Prednisone Placebo

Placebo for Prednisone 5 mg tablet every day for 14 days

DRUG

PF-04171327 25 mg

PF-04171327 25 mg tablet every day for 14 days

OTHER

Prednisone Placebo

Placebo for Prednisone 5 mg tablet every day for 14 days

DRUG

Prednisone 5 mg

Prednisone 5 mg tablet every day for 14 days

OTHER

Placebo for PF-04171327

Placebo for PF-04171327 every day for 14 days

OTHER

Placebo

Placebo tablet every day for 14 days

OTHER

Placebo for PF-04171327

Placebo tablet every day for 14 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-07
Primary Completion
2010-07-29
Completion
2010-07-29

Countries

  • United States
  • Czechia
  • Hong Kong
  • Hungary
  • Russia
  • Serbia
  • Singapore
  • Slovakia
  • South Korea
  • Spain
  • Taiwan
  • Turkey (Türkiye)
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00938587 on ClinicalTrials.gov